IsoPlexis Corporation (ISO) IPO Opens Modestly Lower

Today's IPO for IsoPlexis Corporation (NYSE: ISO) opened for trading at $14.75 after pricing 8,333,000 shares of common stock at a public offering price of $15.00 per share.

Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink are acting as lead book-running managers for the offering.

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies by revenue and by nearly half of comprehensive cancer centers in the U.S.

You May Also Be Interested In

• SpaceX Shares Indicated To Open At $155
• IsoEnergy Announces Results Following Annual General Meeting of Shareholders
• TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'